title: Comparison of susceptibility to extended-spectrum beta-lactam antibiotics and ciprofloxacin among gram-negative bacilli isolated from intensive care units.
abstract: The in vitro activities of extended-spectrum beta-lactam antibiotics (including piperacillin, cefotaxime, ceftriaxone, ceftazidime, cefepime, imipenem, and meropenems) were assessed and compared with the activity of ciprofloxacin against 366 clinical Gram-negative bacilli isolates from the intensive care units of Taichung Veterans General Hospital. The most prevalent species isolated were Pseudomonas aeruginosa and Acinetobacter baumannii. The activities of ceftazidime, cefepime, imipenem, and meropenem against these isolates were comparable to that of ciprofloxacin. Meropenem was found to be the most potent extended-spectrum beta-lactam antibiotic tested and the MIC50s and MIC90s for most of these multiresistant strains were lower than those of imipenem, ceftazidime, and cefepime, except for Stenotrophomonas maltophilia. The extended-spectrum beta-lactam antibiotics that were still active against S. maltophilia were piperacillin and ceftazidime. More than 50% of Enterobacter spp. were resistant to third-generation cephalosporins and piperacillin, but they remained susceptible to carbapenems and cefepime.
authors.affiliation: Section of Infectious Diseases, Taichung Veterans General Hospital, Taiwan, ROC.
authors.forename: P Y
authors.initials: PY
authors.lastname: Liu
authors.forename: Y J
authors.initials: YJ
authors.lastname: Lau
authors.forename: B S
authors.initials: BS
authors.lastname: Hu
authors.forename: J M
authors.initials: JM
authors.lastname: Shyr
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Shi
authors.forename: W S
authors.initials: WS
authors.lastname: Tsai
authors.forename: Y H
authors.initials: YH
authors.lastname: Lin
authors.forename: C Y
authors.initials: CY
authors.lastname: Tseng
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology*; D003428:Cross Infection / Q000188:drug therapy; D004352:Drug Resistance, Microbial; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy; D006801:Humans; D007362:Intensive Care Units; D008826:Microbial Sensitivity Tests; D047090:beta-Lactams
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D047090:beta-Lactams; D002939:Ciprofloxacin